These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 30916388

  • 21. Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report.
    Kim MJ, Lee H, Kim YH, Jin SY, Kim HJ, Oh D, Jeon JS.
    BMC Nephrol; 2021 Mar 10; 22(1):86. PubMed ID: 33691638
    [Abstract] [Full Text] [Related]

  • 22. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C, Ishikura K, Hamada R, Yoshida Y, Kubota W, Okuda Y, Shinozuka S, Harada R, Iyoda S, Fujimura Y, Hamasaki Y, Hataya H, Honda M.
    Nephrology (Carlton); 2018 Jun 10; 23(6):539-545. PubMed ID: 28387984
    [Abstract] [Full Text] [Related]

  • 23. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment.
    Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H.
    J Nephrol; 2017 Feb 10; 30(1):127-134. PubMed ID: 26995002
    [Abstract] [Full Text] [Related]

  • 24. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S, AlDabbagh A, Alamoudi A, Almowarey M, Akl A.
    CEN Case Rep; 2019 May 10; 8(2):139-143. PubMed ID: 30715674
    [Abstract] [Full Text] [Related]

  • 25. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD, Bannerman F, Beresford MW, Oni L.
    BMC Nephrol; 2020 Jun 30; 21(1):245. PubMed ID: 32605540
    [Abstract] [Full Text] [Related]

  • 26. Long-term remission with eculizumab in atypical haemolytic uraemic syndrome.
    Carter S, Hewitt I, Kausman J.
    Nephrology (Carlton); 2017 Feb 30; 22 Suppl 1():7-10. PubMed ID: 28176479
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.
    Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM.
    Nephrol Dial Transplant; 2018 Apr 01; 33(4):635-645. PubMed ID: 29106598
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
    Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG.
    Am J Nephrol; 2018 Apr 01; 48(2):96-107. PubMed ID: 30110670
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Late renal recovery after treatment over 1 year post-onset in an atypical hemolytic uremic syndrome: a case report.
    Kuroki Y, Mitsuiki K, Nakagawa K, Tsuruya K, Katafuchi R, Hirakata H, Nakano T.
    BMC Nephrol; 2020 Jun 22; 21(1):236. PubMed ID: 32571244
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.